Download
s12885-021-08836-y.pdf 1,28MB
WeightNameValue
1000 Titel
  • Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line
1000 Autor/in
  1. Weiner, F. |
  2. Schille, J. T. |
  3. Koczan, D. |
  4. Wu, X.-F. |
  5. Beller, M. |
  6. Junghanss, C. |
  7. Hewicker-Trautwein, M. |
  8. Murua Escobar, H. |
  9. Nolte, I. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-08
1000 Erschienen in
1000 Quellenangabe
  • 21(1):1088
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-021-08836-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501574/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the actual FX-9 molecular mode of action is currently not fully understood.!##!Methods!#!In this study, microarray gene expression analysis comparing FX-9 exposed and unexposed prostate cancer cells (PC-3 representing castration-resistant prostate cancer), followed by pathway analysis and gene annotation to functional processes were performed. Immunocytochemistry staining was performed with selected targets.!##!Results!#!Expression analysis revealed 0.83% of 21,448 differential expressed genes (DEGs) after 6-h exposure of FX-9 and 0.68% DEGs after 12-h exposure thereof. Functional annotation showed that FX-9 primarily caused an activation of inflammatory response by non-canonical nuclear factor-kappa B (NF-κB) signaling. The 6-h samples showed activation of the cell cycle inhibitor CDKN1A which might be involved in the secondary response in 12-h samples. This secondary response predominantly consisted of cell cycle-related changes, with further activation of CDKN1A and inhibition of the transcription factor E2F1, including downstream target genes, resulting in G1-phase arrest. Matching our previous observations on cellular level senescence signaling pathways were also found enriched. To verify these results immunocytochemical staining of p21 Waf1/Cip1 (CDKN1A), E2F1 (E2F1), PAI-1 (SERPNE1), and NFkB2/NFkB p 100 (NFKB2) was performed. Increased expression of p21 Waf1/Cip1 and NFkB2/NFkB p 100 after 24-h exposure to FX-9 was shown. E2F1 and PAI-1 showed no increased expression.!##!Conclusions!#!FX-9 induced G1-phase arrest of PC-3 cells through activation of the cell cycle inhibitor CDKN1A, which was initiated by an inflammatory response of noncanonical NF-κB signaling.
1000 Sacherschließung
lokal Isoquinolines/pharmacology [MeSH]
lokal S Phase Cell Cycle Checkpoints [MeSH]
lokal Antineoplastic Agents/pharmacology [MeSH]
lokal Tissue Array Analysis [MeSH]
lokal Gene Expression/drug effects [MeSH]
lokal G1 Phase Cell Cycle Checkpoints/genetics [MeSH]
lokal Male [MeSH]
lokal Prostatic Neoplasms, Castration-Resistant/genetics [MeSH]
lokal Antimitotic agent
lokal NF-κB signaling
lokal Isoquinolinamine FX-9
lokal G1-phase arrest
lokal Prostate cancer
lokal Cyclin-Dependent Kinase Inhibitor p21/metabolism [MeSH]
lokal PC-3 Cells [MeSH]
lokal Humans [MeSH]
lokal Plasminogen Activator Inhibitor 1/metabolism [MeSH]
lokal Isoquinolines/therapeutic use [MeSH]
lokal G1 Phase Cell Cycle Checkpoints/drug effects [MeSH]
lokal Middle Aged [MeSH]
lokal Prostatic Neoplasms, Castration-Resistant/metabolism [MeSH]
lokal Time Factors [MeSH]
lokal Microarray analysis
lokal E2F1 Transcription Factor/antagonists
lokal NF-kappa B/metabolism [MeSH]
lokal Research
lokal Antineoplastic Agents/therapeutic use [MeSH]
lokal Gene Expression Profiling/methods [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2VpbmVyLCBGLg==|https://frl.publisso.de/adhoc/uri/U2NoaWxsZSwgSi4gVC4=|https://frl.publisso.de/adhoc/uri/S29jemFuLCBELg==|https://frl.publisso.de/adhoc/uri/V3UsIFguLUYu|https://frl.publisso.de/adhoc/uri/QmVsbGVyLCBNLg==|https://frl.publisso.de/adhoc/uri/SnVuZ2hhbnNzLCBDLg==|https://frl.publisso.de/adhoc/uri/SGV3aWNrZXItVHJhdXR3ZWluLCBNLg==|https://frl.publisso.de/adhoc/uri/TXVydWEgRXNjb2JhciwgSC4=|https://frl.publisso.de/adhoc/uri/Tm9sdGUsIEku
1000 Hinweis
  • DeepGreen-ID: 6b78bc0ccbab429fad8bbcae0312bbd0 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463195.rdf
1000 Erstellt am 2023-11-15T17:09:47.846+0100
1000 Erstellt von 322
1000 beschreibt frl:6463195
1000 Zuletzt bearbeitet 2023-11-30T21:12:37.286+0100
1000 Objekt bearb. Thu Nov 30 21:12:37 CET 2023
1000 Vgl. frl:6463195
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463195 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source